{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"title":"Pre-CDE mobilization"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"}],"units":"Participants"}],"title":"Pre-transplant"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"}],"units":"Participants"}],"title":"Hosp discharge"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"}],"units":"Participants"}],"title":"Day 100"}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"}],"units":"Participants"}],"description":"Prevalence of FRE in patients undergoing autologous PBSC transplantation with dose-intense melphalan","groups":[{"description":"Subjects eligible for this study will meet the defined eligibility criteria to undergo autologous transplantation established at the transplant centers as per standard of care (SOC). All adult patients with a diagnosis of multiple myeloma undergoing autologous transplantation after dose-intense melphalan conditioning are candidates for enrollment into this study. These subjects will be approached for enrollment into this study by the transplant attending physician caring for the patient","id":"OG000","title":"Enrolled Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Based on Samples Provided at Specific Timepoints","reportingStatus":"POSTED","timeFrame":"Duration between Apheresis Consultation and Day +100","title":"Prevalence of FRE","type":"PRIMARY","unitOfMeasure":"Participants"}